Company: RGNT
Filing Date: 2025-05-05
Form Type: F-1/A
Source: 0001213900-25-039589
Chunk: 268

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-05
Form: F-1/A
Chunk 268
---
 |   |         30.0 | % |
| Term (years)     |     |   |         0.40 |   |     |   |         0.25 |   |
| Fair value       |     | $ |        4,372 |   |     | $ |        7,405 |   |

<div align='center'>F-17</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 6:- | CONVERTIBLE NOTES (Cont.) |

The Company has performed a sensitivity
analysis of the 2020 Notes which are classified as level 3 financial instruments in the fair value hierarchy. The Company recalculated
the fair value of the 2020 Notes by applying a +/- 5.0% changes to the discount rate used in PWERM.

As of December 31, 2024, a 5.0%
decrease in discount rate would increase the fair value of the 2020 Notes to $4,444; a 5.0% increase in discount rate would decrease
the fair value of the 2020 Notes to $4,305.

c. On March 11, 2023, the Company
converted the 2021 Notes into 88,385 preferred D-2 shares.

The following table presents changes
in the fair value of the 2020 Notes and 2021 Notes:

| Balance as of January 1, 2023                          |     | $ |  6,472 |   |
| Conversion of the 2021 Notes into preferred D-2 shares |     |   | (1,086 | ) |
| Changes in fair value                                  |     |   |  2,019 |   |
| Balance as of December 31, 2023                        |     | $ |  7,405 |   |
| Issuance of additional 2020 Notes                      |     |   |    450 |   |
| Changes in fair value                                  |     |   | (3,483 | ) |
| Balance as of December 31, 2024                        |     | $ |  4,372 |   |

| NOTE 7:- | WARRANT LIABILITY |

| a. | As of January 1, 2023, the Company has issued 167,365 warrants in connection                                                         
 with the issuance of its convertible notes which